Zinc is involved in many biological processes related to inflammation. Plasma zinc levels are reduced in rheumatoid arthritis,1-3 and the reduction of plasma zinc is related to the degree of osteoporosis as determined by the metacarpal index.' Simkin2 reported clinical improvement in patients with rheumatoid arthritis treated with zinc sulphate, but another study failed to confirm this.4 Zinc has also been reported as being beneficial in patients with psoriatic arthritis.5
Patients and methods A 6-month, randomised, double-blind, betweengroup trial was performed. Patients with classical or definite rheumatoid arthritis of at least one year's duration were admitted to the trial if they had active disease uncontrolled by nonsteroidal antiinflammatory drugs. Patients who had received the following drugs in the preceding 3 months were excluded: gold, D-penicillamine, chloroquine, levamisole, and immunosuppressants. Patients received either zinc sulphate 220 mg t.d.s. or identical 'dummy' placebo capsules. In addition to the trial drugs patients continued to receive the antiinflammatory analgesic drugs which they had been taking prior to the study. Patients were assessed initially and then at 6-week intervals for 6 months. The observations made were: (1) Pain, on the 20-point visual analogue scale (VAS). (2) inflated to 20 mmHg, the sum of 2 readings being taken for each hand. (7) Ring size of proximal interphalangeal joints.
Laboratory measurements performed included: haemoglobin, white cell count, erythrocyte sedimentation rate (ESR, Westergren), titre of rheumatoid factor, urea, creatinine, and alkaline phosphatase. The results were analysed by Student's t test.
Twenty-seven patients were admitted to the trial; 14 received zinc (11 female) and 13 placebo (10 female). The mean age was 51 years in the zinc group and 57 years in the placebo group, and the mean disease duration was 4 5 years and 8 years respectively. While both groups had active disease which would allow any drug effect to be clearly demonstrated, the placebo group were slightly more severely affected.
Results
Two patients on zinc were withdrawn, one because of severe indigestion and one for noncompliance. Eight other patients on zinc noticed mild nausea at times, but side effects were not a great problem. Four patients on placebo were withdrawn, 3 due to lack of effect and one due to side effects. Twenty-one patients completed 6 months (12 on zinc and 9 on placebo).
The clinical and laboratory results are shown in Table 1 . Although there was a slight trend towards improvement in both groups of patients, there was no statistically significant change in any of the parameters measured in either group of patients, except for a reduction in ring size (p<o001 in zinc group; p<O0O5 in placebo group), but the difference between the zinc and placebo groups was not significant (p>0 1). There was no significant change in the titre of rheumatoid factor. There was a significant increase in the alkaline phosphatase level in the zinc group (p<O0Ol).
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